欧盟 - 斯洛文尼亚文 - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren, amlodipine, hydrochlorothiazide - hipertenzija - kardiovaskularni sistem - rasitrio je indicirano za zdravljenje esencialne hipertenzije kot nadomestno zdravljenje pri odraslih bolnikih, katerih krvni tlak, ustrezno nadzoruje na kombinacijo aliskiren, amlodipin in ki hkrati na isti odmerek hidroklorotiazid ravni kot kombinacija.

欧盟 - 斯洛文尼亚文 - EMA (European Medicines Agency)

laboratoire francais du fractionnement et des biotechnologies - antithrombin alfa - pomanjkanje antitrombina iii - antitrombotična sredstva - atryn je indiciran za profilakso venske tromboembolije pri operaciji bolnikov s prirojeno pomanjkanjem antitrombina. zdravilo atryn se običajno daje v povezavi s heparinom ali heparinom z nizko molekularno težo.

欧盟 - 斯洛文尼亚文 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - daklatasvir dihidroklorid - hepatitis c, kronični - antivirusi za sistemsko uporabo - zdravilo daklinza je indicirano v kombinaciji z drugimi zdravili za zdravljenje okužbe s kroničnim hepatitisom c (hcv) pri odraslih (glejte poglavja 4. 2, 4. 4 in 5. za hcv genotip določene dejavnosti, glej točki 4. 4 in 5.

欧盟 - 斯洛文尼亚文 - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - human papillomavirus tip 6 l1 beljakovin, human papillomavirus tip 11 l1 beljakovin, human papillomavirus tip 16 l1 beljakovin, human papillomavirus 18. vrsta beljakovine l1 - papillomavirus infections; uterine cervical dysplasia; condylomata acuminata; immunization - cepiva - gardasil je cepivo za uporabo v starosti od 9 let, za preprečevanje:premalignant genitalni lezije (materničnega vratu, vulvar in nožnice), premalignant analni poškodb, raka materničnega vratu in analni raka vzročno povezane z določenimi oncogenic human papillomavirus (hpv) tipov;genitalni bradavice (condyloma acuminata) vzročno povezane s specifičnimi hpv tipov. glej poglavja 4. 4 in 5. 1 za pomembne podatke o podatkih, ki podpirajo to indikacijo. uporaba gardasil je treba v skladu z uradnimi priporočili.

欧盟 - 斯洛文尼亚文 - EMA (European Medicines Agency)

sanofi pasteur s.a. - virus influence (inaktivirano, split) od naslednjih vrst:a/california/7/2009 (h1n1)pdm09 - kot seva a/california/7/2009, nymc x-179a)/hong kong/4801/2014 (h3n2) - kot sev (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - kot sev b/brisbane/60/2008, divji tip) - influenza, human; immunization - cepiva - preprečevanje gripe pri posameznikih, starih 60 let in več, zlasti pri tistih, ki imajo povečano tveganje za povezane zaplete. uporaba idflu mora temeljiti na uradnih priporočilih.

欧盟 - 斯洛文尼亚文 - EMA (European Medicines Agency)

sanofi pasteur europe - virus influence (inaktivirano, split) od naslednjih vrst:a/california/7/2009 (h1n1)pdm09 - kot seva a/california/7/2009, nymc x-179a)/hong kong/4801/2014 (h3n2) - kot sev (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - kot sev b/brisbane/60/2008, divji tip) - influenza, human; immunization - cepiva - preprečevanje gripe pri posameznikih, starih 60 let in več, zlasti pri tistih, ki imajo povečano tveganje za povezane zaplete. uporaba intanza mora temeljiti na uradnih priporočilih.

欧盟 - 斯洛文尼亚文 - EMA (European Medicines Agency)

merck sharp & dohme b.v. - interferon alfa-2b - carcinoid tumor; leukemia, hairy cell; lymphoma, follicular; hepatitis b, chronic; hepatitis c, chronic; leukemia, myelogenous, chronic, bcr-abl positive; melanoma; multiple myeloma - immunostimulants, - kronični hepatitis btreatment odraslih bolnikov s kroničnim hepatitisom b, povezanih z dokazi, hepatitis-b virusno replikacijo (prisotnost dnk hepatitisa b virusa (hbv-dna) in hepatitis b antigen (hbeag), povišana alanin aminotransferase (alt) in histologically dokazano aktivno vnetje jeter in / ali fibroza. kronični hepatitis cbefore začetkom zdravljenja z introna je treba upoštevati, da rezultati iz kliničnih preskušanj primerjavo introna z pegylated interferonom. odraslih patientsintrona je indiciran za zdravljenje odraslih bolnikov s kroničnim hepatitisom c, ki so povišani transaminases brez jeter decompensation in ki so pozitivne za hepatitis c virus-rna (hcv-rna). najboljši način za uporabo introna v ta navedba je v kombinaciji z ribavirin. otrok, tri leta starosti in starejših in adolescentsintrona je navedeno, v kombinaciji režim z ribavirin, za zdravljenje otrok, tri leta starosti in starejših in mladostniki, ki imajo kronični hepatitis c, ki še niso bila obdelana, brez jeter decompensation, in ki so pozitivne za hcv-rna. ko se odločate, da ne odloži zdravljenje do odrasle dobe, je pomembno upoštevati, da je kombinacija terapije povzročile zaviranja rasti, ki se je odrazilo v zmanjšani končni odraslih višina v nekaterih bolnikih, ki. odločitev za zdravljenje mora biti od primera do primera. hairy-celice leukaemiatreatment bolnikov s kosmato levkemijo celic. kronična myelogenous leukaemiamonotherapytreatment odraslih bolnikih s philadelphia-kromosoma - ali bcr/abl-translokacije-pozitivno kronično levkemijo myelogenous. klinične izkušnje kažejo, da hematološko in postopek citogenetske glavnimi / manjšimi odziv je mogoče dobiti v večini bolnikov, zdravljenih. glavni postopek citogenetske odziv je opredeljen z < 34 % ph+ leukaemic celic v kostnem mozgu, ker manjši odziv je ≥ 34 %, vendar < 90 % ph+ celic v mozga. kombinacija therapythe kombinaciji z interferonom alfa-2b in cytarabine (ara-c) upravlja v prvih 12 mesecih zdravljenja je bilo dokazano, da znatno poveča stopnjo večjih postopek citogenetske odgovorov in bistveno podaljša celotno preživetje pri treh letih, ko se je v primerjavi z interferonom alfa-2b monotherapy. več myelomaas vzdrževalna terapija pri bolnikih, ki so dosegli cilj odpust (več kot 50% zmanjšanje v plazmocitom beljakovin) po začetnem indukcijske kemoterapijo. sedanje klinične izkušnje kažejo, da vzdrževanje terapijo z interferonom alfa-2b podaljšuje planoti faze; vendar pa učinki na celotno preživetje niso bile dokončno dokazano,. folikularni lymphomatreatment visoko-tumor-breme, folikularni limfom kot dodatek k ustrezni kombinaciji indukcijske kemoterapijo, kot so sekanje-kot režim. visoko tumorjev obremenitev je opredeljena kot imajo vsaj eno od naslednjih značilnosti: zajetno tumorjev mase (> 7 cm), udeležba tri ali več vozla mesta (> 3 cm), sistemski simptomi (izguba teže > 10 %, pyrexia > 38°c za več kot osem dni, ali nočnega potenje), splenomegaly izven umbilicus, glavni organ, ovira ali stiskanje sindrom, vibracijski ali epiduralno sodelovanje, serous izliv, ali levkemijo. carcinoid tumourtreatment od carcinoid tumorji z limfni vozlišče ali jeter zasevki in z "carcinoid sindrom'. maligni melanomaas adjuvant therapy pri bolnikih, ki so brez bolezni, po operaciji pa so na visoko tveganje za sistemsko ponovitev, e. pri bolnikih s primarno ali periodično (klinično ali patološke) bezgavke-vozlišče.

欧盟 - 斯洛文尼亚文 - EMA (European Medicines Agency)

merck sharp & dohme b.v. - raltegravir - okužbe z virusom hiv - antivirusi za sistemsko uporabo - isentress je navedeno v kombinaciji z drugimi anti-retroviral zdravila za zdravljenje virus človeške imunske pomanjkljivosti (hiv 1) okužbe.

欧盟 - 斯洛文尼亚文 - EMA (European Medicines Agency)

merck sharp & dohme b.v. - pembrolizumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; endometrial neoplasms - antineoplastična sredstva - melanomakeytruda as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma. keytruda as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with stage iib, iic, or with stage iii melanoma and lymph node involvement who have undergone complete resection. non small cell lung carcinoma (nsclc)keytruda as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum based chemotherapy (for selection criteria, see section 5. keytruda as monotherapy is indicated for the first line treatment of metastatic non small cell lung carcinoma in adults whose tumours express pd l1 with a ≥ 50% tumour proportion score (tps) with no egfr or alk positive tumour mutations. keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non squamous non small cell lung carcinoma in adults whose tumours have no egfr or alk positive mutations. keytruda, in combination with carboplatin and either paclitaxel or nab paclitaxel, is indicated for the first line treatment of metastatic squamous non small cell lung carcinoma in adults. keytruda  as monotherapy is indicated for the treatment of locally advanced or metastatic non small cell lung carcinoma in adults whose tumours express pd l1 with a ≥ 1% tps and who have received at least one prior chemotherapy regimen. pri bolnikih z egfr ali alk pozitivnih tumorjev mutacije, ki naj bi prav tako prejel usmerjena terapija pred prejemom keytruda. classical hodgkin lymphoma (chl)keytruda as monotherapy is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical hodgkin lymphoma who have failed autologous stem cell transplant (asct) or following at least two prior therapies when asct is not a treatment option. urothelial carcinomakeytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum containing chemotherapy. keytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin containing chemotherapy and whose tumours express pd l1 with a combined positive score (cps) ≥ 10. head and neck squamous cell carcinoma (hnscc)keytruda, as monotherapy or in combination with platinum and 5 fluorouracil (5 fu) chemotherapy, is indicated for the first line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express pd l1 with a cps ≥ 1. keytruda as monotherapy is indicated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express pd l1 with a ≥ 50% tps and progressing on or after platinum containing chemotherapy. renal cell carcinoma (rcc)keytruda, in combination with axitinib, is indicated for the first line treatment of advanced renal cell carcinoma in adults. keytruda  as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions (for selection criteria, please see section 5. microsatellite instability high (msi-h) or mismatch repair deficient (dmmr) cancerscolorectal cancer (crc)keytruda as monotherapy is indicated for theadults with msi-h or dmmr colorectal cancer in the following settings:first line treatment of metastatic microsatellite instability high (msi h) or mismatch repair deficient (dmmr) colorectal cancer in adults;treatment of unresectable or metastatic colorectal cancer after previous fluoropyrimidine based combination therapy.  non-colorectal cancerskeytruda as monotherapy is indicated for the treatment of the following msi h or dmmr tumours in adults with:advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation;unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. oesophageal carcinomakeytruda, in combination with platinum and fluoropyrimidine based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus or her-2 negative gastroesophageal junction adenocarcinoma, in adults whose tumours express pd l1 with a cps ≥ 10. triple negative breast cancer (tnbc)keytruda, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence. keytruda, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express pd l1 with a cps ≥ 10 and who have not received prior chemotherapy for metastatic disease. endometrial carcinoma (ec)keytruda, in combination with lenvatinib, is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation. cervical cancerkeytruda, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express pd l1 with a cps ≥ 1. gastric or gastro-oesophageal junction (gej) adenocarcinomakeytruda, in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic her2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express pd-l1 with a cps ≥ 1.

欧盟 - 斯洛文尼亚文 - EMA (European Medicines Agency)

merck sharp & dohme b.v. - sitagliptin - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - pri odraslih bolnikih z diabetes tipa 2 bolezni, xelevia je pokazala, da izboljšanje glycaemic nadzor:kot monotherapy:pri bolnikih, neustrezno nadzorovane z dieto in telesno vadbo sami in za katere metformin ni primeren zaradi kontraindikacije ali nestrpnosti;kot dvojno oralna terapija v kombinaciji z:metformin, ko dieto in telesno vadbo plus metformin sam ne zagotavljajo ustrezne glycaemic nadzor;sulfonil sečnine, ko dieto in telesno vadbo plus maksimalne dopustne odmerek sulfonil sečnine sam ne zagotavljajo ustrezne glycaemic nadzor in, če metformin ni primeren zaradi kontraindikacije ali nestrpnosti;a peroksisomski proliferator-activated receptor gama (ppary) agonist (i. a thiazolidinedione) pri uporabi ppary agonist je to primerno in ko dieto in telesno vadbo plus ppary agonist sam ne zagotavljajo ustrezne glycaemic nadzor;kot trojna oralna terapija v kombinaciji z:sulfonil sečnine in metforminom, ko dieto in telesno vadbo plus dvojno zdravljenje s temi zdravili ne zagotavljajo ustrezne glycaemic nadzor;ppary agonist in metforminom pri uporabi ppary agonist je to primerno in ko dieto in telesno vadbo plus dvojno zdravljenje s temi zdravili ne zagotavljajo ustrezne glycaemic nadzor. xelevia je prikazano tudi kot dodatek na inzulinu (z metforminom ali brez), ko dieto in telesno vadbo plus stabilen odmerek insulina ne zagotavljajo ustrezne glycaemic nadzor.